Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — Shareholder Meeting (November 2020)
31 slides from Mach7 Technologies's shareholder meeting presentation, Nov 30, 2020
Slide 1: Mach7 Annual General Meeting 30 November 2020
Mach7 Annual General Meeting 30 November 2020
Slide 2: Opening Remarks
• Opening Remarks • Introductions • Order or Proceedings • Using the Online Platform • Chair’s Address • CEO Presentation • Items of Business • Shareholder General Questions • Voting • Closure 2
Slide 3: Chair's Address: annual results for 2020
We are delighted to present you with our annual results for 2020. This year we regard as having been an extraordinarily successful year for our Company, having doubled our revenue and achieved profitability and positive cash flows for the first time since listing in 2016. These were all goals we set
Slide 4: Mach7 who we are, Our Solutions, FY20 in Review
“Mach7” - who we are Our Solutions FY20 in Review FY21 so Far The Future 4
Slide 5: Hospital systems around the world employ Mach7 Technologies
Hospital systems around the world employ Mach7 Technologies Building a Global Network Large Global Market CUSTOMER FOOTPRINT - 15 COUNTRIES GLOBALLY • Academic Medical Institutions • Competing in Enterprise Imaging and Australia • Community Health Centers PACS markets, globally Canada China • Imagin
Slide 6: Mach7 offers an enterprise-wide platform for medical imaging data
Mach7 offers an enterprise-wide platform for storing, retrieving and viewing all medical imaging data in one vendor neutral ecosystem Core features & functionality include: • Enterprise Diagnostic Viewing • Enterprise Data Management • Enterprise PACS 6
Slide 7: Enterprise imaging is a journey, not a product
Enterprise imaging is a journey, not a product • Mach7 solution can quickly deliver immediate value that can transform and evolve over time to meet future demands Clinical imaging needs to become part of the EMR • Mach7 solution delivers access to critical imaging components of a We help healthcare
Slide 8: Mach7 collaborates with Nuance on AI models
“Mach7 collaborates with Nuance to innovate solutions that can accelerate the at-scale adoption of AI models from the Nuance AI Marketplace within PowerScribe One” AI State of Play AI Visualization R&D Projects • Effective use of AI is still maturing • Mach7 is involved in several discovery projects
Slide 9: Financials, Business, People
Financials Business People • Revenues $18.9M (up 102%) • Successfully completed two capital • Strengthened Board with addition of • EBITDA $3.3M (up 181%) raisings, both well supported by retail and Rob Bazzani, KPMG institutional shareholders • Free cashflow $4.7M (up 263%) • Now employing 85 emplo
Slide 10: COVID Update & Sales Pipeline
COVID 19 Update & Sales Pipeline • COVID-19 has had an unpredictable impact to hospital revenue across the globe • We are seeing signs of image volume returning and hospitals reengaging with previously planned projects and investment • It’s difficult to predict the budgetary impact to our current an
Slide 11: A$10.8M of sales orders so far FY21
New Customers Sales to Existing Customers Boston Scientific Advocate Aurora Health Juniata Cabell Huntington Hospital Saint Francis Diversified Radiology Trinity Health Hospital Authority Hong Kong 12 new customers via our Reseller MaineHealth A$10.8M of sales Partners Raleigh Radiology orders (tota
Slide 12: Trade Shows, Rebranding, New Website
Trade Shows Rebranding New Website U.S. Press Releases • RSNA Virtual Trade Show • New Mach Website LIVE commenced yesterday www.mach7t.com • SIIM 2021 May 26-28, 2021 | Oregon | Portland • 2021 HIMSS Global Health Conference & Exhibition August 9–13, 2021 Las Vegas 12
Slide 13: Client Outlook Integration
Client Outlook Integration IMMEDIATE INTEGRATION SYNERGIES OPTIMIZATION TRANSFORMATION OBJECTIVE I dentify AU$2M in cost I m prove how w e do “One M ach7” Transform our Business consolidation opportunities Business • Integrated Sales, • Future-state org structure Marketing, HR, Legal, designed WHAT
Slide 14: Revenues, EBITDA, Cash outlook
Revenues EBITDA Cash • Expect to deliver positive cash flows for • Expect to deliver minimum A$11.5M in • Expect to deliver positive EBITDA the year, however quarter to quarter will Annual Recurring Revenue (ARR) from growth for FY21 continue to fluctuate due to irregular existing customer base, >90
Slide 15: Organic Growth Strategy, Acquisitive Growth Strategy
Organic Growth strategy Acquisitive Growth Strategy • Investment in marketing for the first • We look forward to fully realizing the time in over three years value and growth from the • Sales team is larger today than it has transformational acquisition of Client been in three years Outlook as a top
Slide 16: To receive and consider the Financial Report
To receive and consider the Financial Report of the Company and its controlled entities and the related Directors’ and Auditor’s Reports in respect of the financial year ended 30 June 2020. 16
Slide 17: Remuneration Report resolution
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT the Remuneration Report of the Company and its controlled entities for the year ended 30 June 2020 be adopted.” Total Available 1 For: Open: Against: Abstain: Votes No. of votes 66,302,785 1,095,239 162,2
Slide 18: Re-election of Mr. Robert Bazzani
To consider and, if thought fit, pass the following resolution as an ordinary resolution: "THAT Mr. Robert Bazzani, having been appointed as a Director on 1 January 2020, retires as a Director of the Company in accordance with article 47(c) of the Constitution and, being eligible and having offered
Slide 19: Re-election of Dr. Eliot Siegel
To consider and, if thought fit, pass the following resolution as an ordinary resolution: "THAT Dr. Eliot Siegel having retired from his office as a Director in accordance with article 47(b) of the Constitution and, being eligible and having offered himself for re-election, be re-elected as a Direct
Slide 20: Performance rights to CEO Michael Lampron
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.14 and for all other purposes, shareholder approval is given for the Company to issue 378,114 performance rights to Mr. Michael Lampron, CEO and Managing Director
Slide 21: Options to Mr. David Chambers
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.11 and for all other purposes, shareholder approval is given for the Company to issue 35,000 options, each to acquire one Share in the Company, to Mr. David Chambe
Slide 22: Options to Dr. Eliot Siegel
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.11 and for all other purposes, shareholder approval is given for the Company to issue 25,000 options, each to acquire one Share in the Company, to Dr. Eliot Siegel
Slide 23: Options to Mr. Robert Bazzani
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.11 and for all other purposes, shareholder approval is given for the Company to issue 25,000 options, each to acquire one Share in the Company, to Mr. Robert Bazza
Slide 24: Shares to Mr. David Chambers
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.11 and for all other purposes, shareholder approval is given for the Company to issue 30,480 Shares to Mr. David Chambers, a Non-Executive Director of the Company,
Slide 25: Shares to Dr. Eliot Siegel
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.11 and for all other purposes, shareholder approval is given for the Company to issue 21,100 Shares to Dr. Eliot Siegel, a Non-Executive Director of the Company, o
Slide 26: Shares to Mr. Robert Bazzani
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT, for the purposes of ASX Listing Rule 10.11 and for all other purposes, shareholder approval is given for the Company to issue 21,100 Shares to Mr. Robert Bazzani, a Non-Executive Director of the Company,
Slide 27: Approval of Long Term Incentive Plan
To consider and, if thought fit, pass the following resolution as an ordinary resolution: “THAT in accordance with Listing Rule 7.2 (Exception 13) as an exception to Listing Rule 7.1 and for all other purposes, approval is given to the Company's Long Term Incentive Plan and the grant of securities u
Slide 28: Approval of additional 10% placement capacity
To consider and, if thought fit, pass the following resolution as a special resolution: “THAT, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to an additional 10% of its issued Equity Securities by way of placements over a 12-month
Slide 29: Questions
QUESTIONS 29
Slide 30: Voting
VOTING 30
Slide 31: Meeting Closed
Meeting Closed Thank you for your attendance
Mach7 Technologies — Shareholder Meeting (November 2020) on 6ix